Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced results of the “Migraine Treatment Needs and Physician
Receptivity” (MINDSET) survey, which demonstrated a significant
unmet need for more efficacious acute migraine treatments and a
high willingness of physicians to prescribe AXS-07 should it meet
the objectives of the ongoing MOMENTUM Phase 3 trial in patients
with difficult-to-treat migraines. MINDSET surveyed 106
neurologists and other migraine-treating physicians, who
collectively treat more than 50,000 migraine patients annually, to
understand physicians’ views of the unmet needs in the acute
treatment of migraine and their potential receptivity to AXS-07.
AXS-07 (MoSEIC™ meloxicam/rizatriptan) is a novel, oral,
investigational medicine with distinct dual mechanisms of action,
currently being evaluated in two Phase 3 efficacy trials (MOMENTUM
and INTERCEPT) for the acute treatment of migraine.
According to the vast majority of physicians
(85%), the most significant unmet need in the acute treatment of
migraine is efficacy, and the majority of their patients who switch
acute migraine treatments (62%) do so because of suboptimal
efficacy. Physicians would prescribe AXS-07 to 37% of their
patients who experience difficult-to-treat migraine if it
demonstrates efficacy over placebo in the ongoing MOMENTUM trial in
patients with a history of inadequate response. If AXS-07
demonstrates superior efficacy to rizatriptan as assessed in the
MOMENTUM trial, approximately 90% of physicians report they are
more likely to prescribe AXS-07 over currently available
treatments, and over other emerging therapies, including oral
CGRPs, that have not demonstrated superiority to current therapies.
More than half (56%) of physicians report that they are
significantly or moderately more likely to prescribe AXS-07 over
these other treatments. Results of the survey also indicate that
treating physicians are significantly concerned that suboptimal
response to acute migraine treatments may lead to progression to
chronic migraine. Furthermore, the majority of physicians believe
it is very important to administer acute treatments at the earliest
sign of migraine pain.
“Migraine causes people to lose their jobs, lose
their relationships and lose their self-identify,” said Herriot
Tabuteau, M.D., Chief Executive Officer of Axsome. “Results of the
MINDSET survey of migraine-treating physicians highlight the
significant need for more effective acute treatments for this
debilitating neurological disease, and the desire of physicians for
new treatments that demonstrate improvement over the current
standard of care. The survey results therefore support the design
of the ongoing MOMENTUM Phase 3 trial of AXS-07, which is being
conducted in patients with a history of inadequate response to
prior acute treatments, and which incorporates the very potent
active comparator rizatriptan.”
Key Topline Findings from the MINDSET
Survey
Participants and Time of Conduct
- The survey respondents consisted of
a total of 106 physicians, of whom 76% are neurologists and 24% are
primary care physicians. Collectively, the survey respondents
personally see and treat 51,504 migraine patients at least once per
year.
- The survey was fielded in October
2019.
Treatment Needs in Migraine
- Improved efficacy is the most
significant unmet need in the acute treatment of migraine,
according to 85% of physicians, far outpacing other areas (e.g.
tolerability, safety, mode of administration). The majority of
their patients who switch acute migraine treatments (62%) do so
because of suboptimal efficacy.
- A significant number of migraine
patients experience suboptimal response to current treatments or
experience difficult-to-treat migraines (39% and 31%,
respectively), according to treating physicians.
- Increased risk of progression from
episodic to chronic migraine associated with suboptimal acute
treatment is a key concern for treating physicians, with 76%
reporting that they are significantly or moderately concerned.
- Early treatment of migraine (at the
earliest sign of pain) is believed to be very important by 90% of
treating physicians.
Willingness to Prescribe AXS-07
- If AXS-07 demonstrates superior
efficacy over placebo in patients with a history of inadequate
response to prior acute treatments, as assessed in the ongoing
MOMENTUM trial, physicians indicate they would prescribe AXS-07 to
37% of their patients with difficult-to-treat migraines.
- If AXS-07 demonstrates superior
efficacy over rizatriptan, as assessed in the ongoing MOMENTUM
trial, 91% of physicians report that they are more likely to
prescribe AXS-07 over currently available treatments, with 56%
reporting that they are significantly or moderately more likely to
prescribe AXS-07.
- If AXS-07 demonstrates superior
efficacy over rizatriptan as assessed in the ongoing MOMENTUM
trial, 87% of physicians report that they are more likely to
prescribe AXS-07 over other drugs in development, including oral
CGRPs, that have not demonstrated superior efficacy to current
treatments, with 56% reporting that they are significantly or
moderately more likely to prescribe AXS-07.
About the MOMENTUM Trial in Patients
with History of Inadequate Response
MOMENTUM (Maximizing Outcomes in Treating Acute
Migraine) is a Phase 3, randomized, double-blind, multicenter,
controlled trial to assess the efficacy and safety of AXS-07 in the
acute treatment of moderate and severe migraine in patients with a
history of inadequate response to prior acute treatments.
Approximately 875 eligible patients will be randomized in a 2:2:2:1
ratio to treatment with AXS-07, rizatriptan, MoSEIC™ meloxicam, or
placebo. The two co-primary endpoints of the trial are the
proportion of patients who are free from headache pain two hours
after dosing, and the proportion of patients who no longer suffer
from their most bothersome migraine-associated symptom (nausea,
photophobia, or phonophobia) two hours after dosing, for AXS-07 as
compared to placebo. Superiority of AXS-07 to the rizatriptan and
meloxicam arms (component contribution) will be established based
on sustained freedom from headache pain from two to 24 hours after
dosing. The MOMENTUM study is being conducted pursuant to an FDA
Special Protocol Assessment (SPA).
About the INTERCEPT Trial Evaluating
Early Treatment
INTERCEPT (Initiating Early Control of Migraine
Pain and Associated Symptoms) is a Phase 3, randomized,
double-blind, multicenter, placebo-controlled trial evaluating the
early treatment of migraine with AXS-07. Approximately 300 patients
will be randomized in a 1:1 ratio to treatment with AXS-07 or
placebo. Patients are to administer AXS-07 at the earliest sign of
migraine pain. The two co-primary endpoints of the trial are the
proportion of patients who are free from headache pain two hours
after dosing, and the proportion of patients who no longer suffer
from their most bothersome migraine-associated symptom (nausea,
photophobia, or phonophobia) two hours after dosing.
About Migraine
Over 37 million Americans suffer from migraine
according to the Centers for Disease Control, and it is the leading
cause of disability among neurological disorders in the United
States according to the American Migraine Foundation. Migraine is
characterized by recurrent attacks of pulsating, often severe and
disabling head pain associated with nausea, and sensitivity to
light and or sound. It is estimated that migraine accounts for $78
billion in direct (e.g. doctor visits, medications) and indirect
(e.g. missed work, lost productivity) costs each year in the United
States [1]. Published surveys of migraine sufferers indicate that
more than 70% are not fully satisfied with their current treatment,
that nearly 80% would try a new therapy, and that they desire
treatments that work faster, more consistently, and result in less
symptom recurrence [2,3].
About AXS-07
AXS-07 is a novel, oral, investigational
medicine with distinct dual mechanisms of action under development
for the acute treatment of migraine. AXS-07 consists of MoSEIC™
meloxicam and rizatriptan. Meloxicam is a new molecular entity for
migraine enabled by Axsome’s MoSEIC (Molecular Solubility Enhanced
Inclusion Complex) technology, which results in rapid absorption of
meloxicam while maintaining a long plasma half-life. Meloxicam is a
COX-2 preferential non-steroidal anti-inflammatory drug and
rizatriptan is a 5-HT1B/D agonist. AXS-07 is designed to provide
rapid, enhanced and consistent relief of migraine, with reduced
symptom recurrence. AXS-07 is not approved by the FDA.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s core CNS product
candidate portfolio includes four clinical-stage candidates,
AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is currently in a Phase
3 trial in treatment resistant depression (TRD), a Phase 3 trial in
major depressive disorder (MDD), and a Phase 2/3 trial in agitation
associated with Alzheimer’s disease (AD). AXS-05 is also being
developed for smoking cessation treatment. AXS-07 is currently in
two Phase 3 trials for the acute treatment of migraine. AXS-12 is
currently in a Phase 2 trial in narcolepsy. AXS-05, AXS-07, AXS-09,
and AXS-12 are investigational drug products not approved by the
FDA. For more information, please visit the Company’s website at
axsome.com. The Company may occasionally disseminate material,
nonpublic information on the company website.
References
1. Gooch CL, Pracht E, Borenstein AR. The burden
of neurological disease in the United States: A summary report and
call to action. Ann Neurol. 2017 Apr; 81(4):479-484.
2. Smelt AF, Louter MA, Kies DA, Blom JW,
Terwindt GM, van der Heijden GJ, De Gucht V, Ferrari MD, Assendelft
WJ. What do patients consider to be the most important outcomes for
effectiveness studies on migraine treatment? Results of a Delphi
study. PLoS One. 2014 Jun 16;9(6):e98933.
3. Lipton RB, Stewart WF. Acute migraine
therapy: do doctors understand what patients with migraine want
from therapy? Headache. 1999;39(suppl 2):S20-S26.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected expenses), futility analyses and
receipt of interim results, which are not necessarily indicative of
the final results of our ongoing clinical trials, and the number or
type of studies or nature of results necessary to support the
filing of a new drug application (“NDA”) for any of our current
product candidates; our ability to fund additional clinical trials
to continue the advancement of our product candidates; the timing
of and our ability to obtain and maintain U.S. Food and Drug
Administration (“FDA”) or other regulatory authority approval of,
or other action with respect to, our product candidates (including,
but not limited to, FDA’s agreement with the Company’s plan to
discontinue the bupropion treatment arm of the ADVANCE-1 study in
accordance with the independent data monitoring committee’s
recommendations); the potential for the ASCEND clinical trial to
provide a basis for approval of AXS-05 for the treatment of major
depressive disorder and accelerate its development timeline and
commercial path to patients; the Company’s ability to successfully
defend its intellectual property or obtain the necessary licenses
at a cost acceptable to the Company, if at all; the successful
implementation of the Company’s research and development programs
and collaborations; the success of the Company’s license
agreements; the acceptance by the market of the Company’s product
candidates, if approved; the Company’s anticipated capital
requirements, including the Company’s anticipated cash runway and
the Company’s current expectations regarding its plans for future
equity financings prior to the readout from its Phase 3 trials; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contact: Mark Jacobson Senior Vice
President, Operations Axsome Therapeutics, Inc. 200 Broadway, 3rd
Floor New York, NY 10038 Tel: 212-332-3243 Email:
mjacobson@axsome.com www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024